CARSgen Wins China’s Fifth CAR-T Approval But Pricing Dilemma Unresolved

 
• By Dexter Jie Yan
  
patient access
CARSgen and partner Huadong face formidable task to expand patient access to their CAR-T therapy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia